Analysts have raised their price target for Hyperfine from $1.42 to $1.70. They cite higher projected revenue growth and a slightly lower discount rate as reasons for a more bullish outlook.
What's in the News
- Hyperfine announced the launch of PULSE, a subscription-based platform that offers researchers and developers advanced tools and access to proprietary imaging sequences for the portable Swoop MRI system.
- Optive AI software received UK Conformity Assessment approval and began rollout to existing customers, enabling significant improvements in image quality for Swoop MRI users in the US, UK, and Europe.
- Enrollment of 100 patients in the NEURO PMR study was successfully completed, supporting Hyperfine's expansion into outpatient neurology offices and broader adoption of portable MRI technology.
- The PRIME study commenced at Yale to evaluate the impact of AI-powered portable MRI as a triage tool in emergency departments for a diverse set of brain-related medical conditions.
- Promising interim results from the CARE PMR study showed the Swoop system achieved 100% sensitivity in detecting ARIA-E in Alzheimer's patients undergoing Lecanemab therapy, according to the Alzheimer's Association International Conference 2025.
Valuation Changes
- Consensus Analyst Price Target increased from $1.42 to $1.70, reflecting a higher assessed fair value for Hyperfine shares.
- Discount Rate decreased moderately from 7.47% to 7.39%, which signals slightly lower risk assumptions in updated forecasts.
- Revenue Growth expectation rose significantly from 28.3% to 44.1%, which indicates a substantially improved sales outlook.
- Net Profit Margin estimate edged down from 12.49% to 12.32%, which suggests a marginally less optimistic profitability projection.
- Future P/E multiple declined from 59.3x to 50.8x, implying that analysts foresee stronger earnings performance in future periods.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.